PDX Pharma was granted a new EU patent

PDX Pharma was granted a new EU patent (EP3270932) on August 21, 2024, covering the composition and method of use for our innovative Pdx-NP™ nanoparticle platform. Developed as a polymer-coated mesoporous silica alternative to lipid-based particles, which tend to home to the liver, Pdx-NP™ is the core nanotechnology behind all of PDX Pharmaceuticals’ pipelines. These include the HER2-targeted therapy T-siHER2-NP™, the radiation sensitizer PETTRA™, the immunotherapeutics ARAC™ and AIRISE™, the nano-cytokine CK-NP™ for cancer treatments, and the AIRISE-VAC™ vaccine platforms for infectious diseases. This patent strengthens our IP beyond the U.S. patent (US11207428) issued in December 2021, bolstering our commercialization efforts. Congratulations to the inventors from PDX Pharma and OHSU, including Drs. Wassana Yantasee, Worapol (Boom) Ngamcherdtrakul, Joe Gray, Jingga Morry, and David Castro.